FDA approves treatment for chronic graft versus host disease

By Newsroom America Feeds at 2 Aug 2017

The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569710.htm

Categories:
Tags:

[D] [Digg] [FB] [R] [SU] [Tweet] [G]

NEWSMAIL